Interleukin-2-induces development of denditric cells from cord blood CD34+ cells.
Dendritic cells (DC) have been shown to develop along a myeloid or lymphoid lineage of differentiation propagated from bone marrow or early thymic precursor cells with hematopoietic cytokines. In our study, we have induced growth and differentiation of DC from cord blood CD34+ cells initiated in interleukin-2 (IL-2) alone or in IL-2 + stem cell factor (SCF) + tumor necrosis factor alpha (TNF-alpha)-supplemented medium and cultured with IL-2 or IL-2 + SCF for 28-35 days. Dendritic morphology and antigenic phenotype of DC grown with IL-2 were characteristic for DC cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF). Growth and differentiation of DC was followed by an increase in expression of MHC II and co-stimulating molecules CD80 and CD86. We have also shown the expression of the IL-2 receptor (IL-2R) gamma-chain in CD34+ cells after 2-3 days of culture with IL-2 alone. The co-expression of the IL-2R alpha, beta, and gamma subunits in both DC cultured with IL-2- or GM-CSF-containing cocktail of cytokines was also shown. The time curve for induction of IL-2R demonstrated low levels of subunit expression at the beginning of culture. The number of CD1a cells co-expressing CD25, CD122, and CDgamma increased to about 24-68 and to 78-95% after 21 and 28-35 days, respectively. Development of natural killer cells was shown along with DC. The proportion of CD56+ cells and cytotoxicity increased in a time-dependent manner.
Bykovskaja
S N
SN
Department of Laboratory Medicine, Cardiovascular Research, and Radiation Oncology of the Allegheny-Singer Research Institute, Allegheny University of the Health Sciences, Pittsburgh, Pennsylvania, USA.
Buffo
M J
MJ
Bunker
M
M
Zhang
H
H
Majors
A
A
Herbert
M
M
Lokshin
A
A
Levitt
M L
ML
Jaja
A
A
Scalise
D
D
Kosiban
D
D
Evans
C
C
Marks
S
S
Shogan
J
J
D015703:Antigens, CD / Q000378:metabolism; D018952:Antigens, CD34 / Q000032:analysis; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen; D002454:Cell Differentiation; D002455:Cell Division; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology; D005312:Fetal Blood / Q000166:cytology*; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007111:Immunity, Cellular; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000166:cytology; D007959:Lymphocyte Culture Test, Mixed; D008562:Membrane Glycoproteins / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D019089:Stem Cell Factor / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D015703:Antigens, CD; D018952:Antigens, CD34; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C497964:CD86 protein, human; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D015375:Receptors, Interleukin-2; D019089:Stem Cell Factor; D014409:Tumor Necrosis Factor-alpha